Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01451723 · ClinicalTrials.gov registry record · Phase 2
Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II
A Phase 2 study, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01451723 is a Phase 2 study that was terminated before completion, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 11 participants.
The verdict
NCT01451723, a Phase 2 study, was terminated before completion, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The hypothesis is that Polyphenon E can protect brain cells in patients with Multiple Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate (a chemical that reflects the number of neurons and their metabolism) over one year between people with MS treated with Polyphenon E at a dose of 400mg twice a day and people with MS treated with a matching sugar pill.
Interventions
- OTHER Placebo
- DRUG Polyphenon E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01451723
The ClinicalTrials.gov registry entry for NCT01451723 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louisiana State University Health Sciences Center in New Orleans, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01451723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01451723 about?
NCT01451723 is a clinical study titled "Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II". The hypothesis is that Polyphenon E can protect brain cells in patients with Multiple Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate (a chemical that reflects the number of neurons and their metabolism) over one year between people with MS treated with P...
What is the current status of trial NCT01451723?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2011-07. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01451723?
The interventions under investigation include: Placebo (OTHER), Polyphenon E (DRUG).
Who is sponsoring clinical trial NCT01451723?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.